Previous studies showed that CHAC1 protein expression is upregulated in glioma cells in response to treatment with Temozolomide (TMZ), the most common antiglioma chemotherapeutic agent, and that CHAC1 overexpression enhances glioma apoptotic death (Chen et al., 2017). This evidence concerns the gene CHAC1 and central nervous system cancer.